Authors:
Monali Tayade, Jignesh Rawal
Download free PDF
Critical Care Devices Market Size & Share 2026-2035
Report ID: GMI3936
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Critical Care Devices Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Critical Care Devices Market Size
The critical care devices market was valued at USD 63.6 billion in 2025 and USD 67.3 billion in 2026 to USD 108.1 billion by 2035, at a 5.4% CAGR for 2026–2035. The market includes defibrillators, multiparameter monitors, ECG devices, dialysis and CRRT systems, infusion pumps, ventilators, feeding tubes, and anesthesia monitors used in high-acuity hospitals, ambulatory surgical centers, and specialty settings.
Critical Care Devices Market Key Takeaways
Market Leader: Medtronic plc led with over 11% market share in 2025.
Leading Players: Top 5 players in this market include Medtronic plc, Koninklijke Philips N.V., GE Healthcare, Drägerwerk AG & Co. KGaA, Becton, Dickinson and Company (BD), which collectively held a market share of 45% in 2025.
Critical-care capacity remains uneven. OECD countries averaged 16.9 ICU beds per 100,000 people in 2021, while capacity differed sharply across countries. Asia-Pacific critical-care bed availability increased from 3.0 to 9.4 beds per 100,000 people between 2017 and 2022 across 19 studied countries and regions. This creates two demand patterns: replacement of connected, higher-acuity systems in established ICUs and first-time equipment purchases in expanding facilities.
North America accounted for USD 23.8 billion, or 37.5%, of 2025 demand Europe represented USD 16.9 billion, and Asia Pacific USD 16.0 billion. Defibrillators were the largest product category at USD 14.8 billion, while CRRT machines were the fastest-growing category at 7.8% CAGR.
GMI Analyst View
The 5.4% forecast growth rate reflects a change in the equipment mix rather than a simple expansion in bed count. New ICU capacity requires foundational monitoring, infusion, ventilation, and renal-support equipment, while mature providers are replacing stand-alone hardware with interoperable platforms that can consolidate alarms and patient data. The strongest growth in CRRT is consistent with the high incidence of acute kidney injury among critically ill patients, while connected monitoring and ventilation systems create a separate upgrade cycle in established hospitals,.
Key Drivers
Rising demand for intensive care units
Capacity additions create equipment demand at the bed level: monitoring, infusion, ventilation, and access to renal replacement become part of the operating model for high-acuity units. The gap between high-income countries, which averaged 12.79 ICU beds per 100,000 people, and lower-middle-income countries, at 2.05, indicates substantial unmet infrastructure demand. Asia-Pacific expansion has been particularly material, supporting a multi-year procurement cycle rather than isolated emergency purchasing.
Growing incidence of chronic diseases throughout the globe
Cardiovascular disease drove 19.2 million deaths in 2023, with 626 million people living with the condition. Chronic kidney disease affected 788 million adults globally in 2023. These disease burdens sustain demand for defibrillation, ECG, hemodynamic monitoring, dialysis, and CRRT equipment because acute decompensation and treatment complications frequently require high-acuity monitoring and intervention.
Technological advancements in critical care
AI-enabled clinical support and open connectivity are changing capital-equipment decisions from single-device purchases to workflow investments. AI interventions can extend clinician oversight capacity in critical care settings. Philips' July 2025 SDC partnership with Dräger, Hamilton Medical, Getinge, and B. Braun supports bidirectional device data exchange and consolidated patient views across mixed-vendor environments. The commercial consequence is greater value placed on interoperability, service capability, and installed-base compatibility.
Surging demand for ventilators for better management of diseases
COPD was the third leading cause of death globally in 2023, causing 3.4 million deaths. Ventilator demand therefore extends beyond pandemic replacement cycles to chronic respiratory disease, ARDS, perioperative respiratory failure, and neonatal care. Getinge reported ventilator demand as a growth contributor in Acute Care Therapies during 2025.
Key Restraints
Lack of skilled professionals
Critical-care equipment requires trained personnel to operate, interpret, troubleshoot, and maintain it. The global nursing shortage stood at 5.8 million in 2023, and workforce distribution remains uneven across countries. Low-resource ICUs have reported nurse-to-patient ratios of 1:4 or worse, compared with recommended ratios of 1:1 or 1:2. These constraints can delay purchases, limit utilization of advanced functionality, and increase the importance of intuitive interfaces, training, and remote support.
High cost of critical care devices
The economic barrier extends beyond device acquisition to installation, validation, consumables, software, maintenance, and training. CRRT is particularly demanding because treatment requires recurring filters, circuits, and solutions cost has been identified as an adoption barrier in developing settings. In budget-constrained systems, suppliers must demonstrate lifecycle economics rather than clinical performance alone.
GMI Analyst View
Demand fundamentals are strong, but epidemiology does not translate automatically into equipment revenue. Workforce capacity determines whether hospitals can operate advanced systems effectively, while financing determines whether providers can acquire them. AI-supported monitoring and interoperable workflows may partially ease staffing pressure, but they also raise implementation requirements. Suppliers that combine training, service, consumables, and financing with equipment are better positioned where capital budgets and specialist staffing constrain adoption.
Critical Care Devices Market Segment Analysis
By Product Type
Defibrillators generated USD 14.8 billion in 2025, equal to 23.3% of market revenue, and are forecast to grow at 6.1% CAGR. Their position is tied to the continuing cardiovascular disease burden. Multiparameter monitors represented USD 11.1 billion and are expected to grow at 6.2% CAGR as connected bedside data becomes central to ICU workflow,.
ECG devices accounted for USD 8.0 billion and are comparatively mature, with 3.8% CAGR. Hemodialysis machines represented USD 6.7 billion, while infusion pumps generated USD 6.8 billion kidney disease prevalence supports renal-device demand, and pump replacement increasingly centers on precision and integration,. ICU Medical received FDA clearances in April 2025 for Plum Solo and Plum Duo pumps with stated ±3% delivery accuracy.
Ventilators represented USD 4.7 billion and are projected to grow at 6.7% CAGR. Getinge's Neural Pressure Support for Servo-u targets COPD and ARDS applications. Feeding tubes accounted for USD 2.9 billion, anesthesia monitors USD 1.6 billion, CRRT machines USD 1.5 billion, and other products USD 5.4 billion in 2025. CRRT's 7.8% CAGR reflects its role in treating hemodynamically unstable patients with acute kidney injury.
By Application
Cardiology was the largest application at approximately USD 22.7 billion, or 35.7% of 2025 revenue. Renal care generated USD 14.6 billion and is forecast to grow at 6.8% CAGR, supported by both chronic kidney disease and acute kidney injury demand,. Neurology accounted for USD 7.8 billion and is expected to expand at 6.2% CAGR. Other applications include pulmonology, trauma, sepsis, toxicology, and pediatric critical care.
By End Use
Hospitals accounted for approximately USD 27.4 billion, or 43.1%, of 2025 revenue. Their scale supports multi-device purchasing, integration projects, and long-term service arrangements. Ambulatory surgical centers are projected to grow at 6.2% CAGR, and specialty clinics at 5.8% CAGR, as advanced monitoring, infusion, anesthesia, and renal-care capabilities extend beyond inpatient hospitals.
GMI Analyst View
Segment growth is uneven because the market is separating into foundational devices, mature diagnostic tools, and high-acuity therapeutic platforms. CRRT and renal care outpace the overall market because kidney injury links chronic disease with acute ICU instability,. Connected monitoring, precision infusion, and advanced ventilation compete on clinical workflow and risk reduction rather than hardware specifications alone. Hospitals retain purchasing power, but ASC and specialty-clinic growth makes portable, scalable, and serviceable systems increasingly important.
Critical Care Devices Market Regional Analysis
North America
North America generated USD 23.8 billion in 2025 and held 37.5% market share, with approximately 5.0% CAGR projected through 2035. The U.S. market advanced from USD 19.1 billion in 2022 to USD 22.2 billion in 2025. High adoption of premium monitoring, ventilation, cardiac, and renal platforms is supported by large hospital systems and reimbursement for high-acuity procedures. U.S. COPD prevalence, with approximately 11.1 million diagnosed adults in 2023, reinforces respiratory-care demand.
Europe
Europe represented USD 16.9 billion in 2025, or approximately 26.5% of global revenue, and is projected to grow at roughly 5.1% CAGR. Demand is sustained by aging populations, universal-care procurement systems, and replacement of installed ICU equipment. Germany's ICU capacity was approximately 33.9 beds per 100,000 population, creating a substantial installed base for ventilation and monitoring platforms.
Asia Pacific
Asia Pacific reached approximately USD 16.0 billion in 2025 and is projected to grow at 6.2% CAGR, the fastest pace among major regions. The region's ICU-bed expansion supplies a structural demand base for monitors, ventilators, infusion systems, and renal equipment. India's 10.9 critical-care beds per 100,000 people, Japan's 10.7, and South Korea's 17.6 illustrate the range of market maturity and procurement requirements.
Latin America
Latin America generated approximately USD 4.6 billion in 2025 and is forecast to grow at approximately 5.7% CAGR. Demand is concentrated in larger urban hospitals and private providers, while imported-equipment costs, currency volatility, and public-sector budgets can extend replacement cycles.
Middle East and Africa
The Middle East and Africa market totaled approximately USD 2.3 billion in 2025 and is projected to expand at approximately 5.3% CAGR. Gulf markets provide a higher-acuity procurement opportunity, while broader regional growth is constrained by staffing and financing. Saudi Arabia's reported ICU capacity of 21.7 beds per 100,000 people indicates a relatively developed critical-care infrastructure within the region.
GMI Analyst View
Regional expansion is driven by different mechanisms. North America and Europe remain replacement-led markets, where interoperability and lifecycle performance shape vendor selection. Asia Pacific's 6.2% CAGR is more capacity-led: new beds create demand across the device stack, but procurement varies substantially by national infrastructure and cost sensitivity,. Latin America and MEA offer growth but require suppliers to address financing, training, service coverage, and consumable continuity rather than relying on product performance alone.
Critical Care Devices Market Share & Competitive Landscape
The market is moderately concentrated, with Medtronic, Koninklijke Philips, GE Healthcare, Drägerwerk, and Becton Dickinson collectively accounting for approximately 45% of global revenue. Competitive advantage increasingly depends on integrated platforms, connectivity, clinical software, service reach, and total cost of ownership.
Medtronic reported FY2024 revenue of USD 32.364 billion, including USD 1.908 billion from Acute Care & Monitoring. In April 2025, it received FDA approval for the OmniaSecure defibrillation lead.
Koninklijke Philips competes through IntelliVue monitoring, critical-care informatics, and connectivity. Its 2025 SDC initiative with multiple device manufacturers positions interoperability as a strategic differentiator.
GE Healthcare competes in bedside monitoring, ventilation, imaging, and workflow technology. Its scale in medical technology supports integrated equipment purchasing by large hospital systems.
Drägerwerk remains focused on ventilation, monitoring, anesthesia, and ICU infrastructure. Its participation in the Philips SDC partnership aligns its portfolio with open device connectivity.
Becton, Dickinson and Company completed its USD 4.2 billion acquisition of Edwards Lifesciences' Critical Care business in September 2024, creating BD Advanced Patient Monitoring. The acquired portfolio extends BD's capabilities in hemodynamic monitoring and decision support.
Fresenius Medical Care served approximately 299,000 dialysis patients through 3,675 clinics and reported approximately 50% global hemodialysis-product market share. Its 5008X high-volume hemodiafiltration system received FDA clearance, with U.S. commercialization planned for 2026.
Getinge derived more than half of 2024 group sales from Acute Care Therapies. Its Servo portfolio includes Neural Pressure Support and neonatal ventilation options, extending the company's reach in differentiated ventilator applications,.
Hamilton Medical participates in the Philips SDC partnership and is associated with INTELLiVENT-ASV intelligent ventilation capability.
ICU Medical received FDA clearances for Plum Solo and Plum Duo infusion pumps in April 2025, reinforcing its position in precision infusion therapy.
Abbott Laboratories participates through cardiovascular, cardiac rhythm management, structural-heart, and point-of-care diagnostics portfolios. It reported USD 44.33 billion in annual revenue.
B. Braun Melsungen supplies infusion, nutrition, and renal-care systems and participates in the Philips SDC partnership.
Baxter supplies hospital technologies, infusion, renal-care, and vital-sign monitoring solutions. Its Welch Allyn Connex 360 monitor was launched in late 2025.
Asahi Kasei Corporation, through ZOLL Medical, expanded its respiratory portfolio through the acquisition of selected Vyaire ventilator lines in 2024. ZOLL's Zenix monitor/defibrillator received FDA approval and EU MDR certification in 2025.
Boston Scientific Corporation reported USD 19.5 billion in 2024 revenue and participates in cardiovascular and endoscopy-based acute-care applications.
Recent Industry Developments
September 3, 2024 - BD completes Edwards Critical Care acquisition
BD completed its USD 4.2 billion acquisition of Edwards Lifesciences' Critical Care business and renamed it BD Advanced Patient Monitoring.
October 14, 2024 - ZOLL acquires selected Vyaire ventilator lines
ZOLL completed the acquisition of bellavista, fabian, LTV, 3100 HFOV, and Infant Flow LP product lines, expanding its respiratory portfolio in more than 140 countries.
February 2024 - Fresenius Medical Care receives 5008X FDA clearance
Fresenius Medical Care received FDA 510(k) clearance for its 5008X high-volume hemodiafiltration system.
April 7, 2025 - ICU Medical receives Plum pump clearances
ICU Medical received FDA 510(k) clearances for the Plum Solo and Plum Duo precision IV pumps.
April 25, 2025 - Medtronic receives OmniaSecure approval
Medtronic received FDA approval for its OmniaSecure lumenless defibrillation lead.
July 9, 2025 - Philips announces SDC partnerships
Philips announced an SDC interoperability initiative with Dräger, Hamilton Medical, Getinge, and B. Braun.
2025 - Getinge expands Servo ventilation capabilities
Getinge introduced Neural Pressure Support for Servo-u and extended Servo-c ventilation to neonatal patients weighing as little as 500 grams,.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →